Summary
Johnson & Johnson (JNJ) announced on June 17, 2013, a definitive agreement to acquire Aragon Pharmaceuticals, Inc., a company specializing in the discovery and development of drugs for hormonally-driven cancers. This strategic move signals JNJ's intent to bolster its oncology pipeline, a key growth area. The acquisition involves an upfront cash payment of $650 million, with potential for additional milestone-based payments up to $350 million, totaling a maximum consideration of $1 billion.
Key Highlights
- 1JNJ to acquire Aragon Pharmaceuticals, Inc., a privately-held drug discovery and development company focused on hormonally-driven cancers.
- 2Acquisition aims to enhance JNJ's oncology portfolio.
- 3Upfront payment of $650 million in cash.
- 4Potential for contingent payments up to $350 million based on achieving predetermined milestones.
- 5Total potential transaction value of up to $1 billion.
- 6Expected closing in the third quarter of 2013.
- 7Transaction is subject to customary closing conditions, including antitrust clearance under the Hart-Scott-Rodino Act.
Frequently Asked Questions
The acquisition of Aragon Pharmaceuticals is intended to strengthen Johnson & Johnson's oncology pipeline, specifically in the area of hormonally-driven cancers. This aligns with JNJ's strategy to invest in and grow its pharmaceutical segment, particularly in therapeutic areas with significant unmet medical needs.
The total potential cost for this acquisition is up to $1 billion. This includes an upfront cash payment of $650 million and contingent payments of up to $350 million, which are dependent on Aragon achieving specific development and regulatory milestones.
Prior to closing, Aragon will spin off its assets, excluding the androgen receptor antagonist program, into a newly formed company. Johnson & Johnson will not have any ownership or rights to these spun-off products or programs.
The transaction is anticipated to close during the third quarter of 2013, subject to the satisfaction of all customary closing conditions, including regulatory approvals.